Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study

Table 5

Details of three patients who had seizures as an adverse event after cellular therapy.

	Patient I	Patient II	Patient III
Type of seizures (before and after intervention)	Pre-GTC; Post-GTC	Pre-No seizure; Post-GTC	Pre-No seizures; Post-GTC
Number of seizure episodes after intervention	One	Multiple	Two
Duration in months between the cellular therapy and first seizure episode	Six	Four	Three
Duration in months over which seizure episodes recurred	No recurrence	Ten	Three
Medication used for seizure control	Midazolam	Sodium Valproate dose was doubled. Clobazam was discontinued and Lamotrigine was added	Sodium Valproate
Seizure related complications	None	None	None
Effect of seizures on clinical improvement	There was no deterioration in the baseline and the marked clinical improvement was maintained	There was no deterioration in the baseline and the marked clinical improvement was maintained	There was no deterioration in the baseline and the marked clinical improvement was maintained